ETON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ETON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Eton Pharmaceuticals's share price is $3.55. Eton Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.26. Hence, Eton Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is 13.60.
The historical rank and industry rank for Eton Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:
During the past 7 years, Eton Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 49.63. The lowest was 9.92. And the median was 16.82.
Eton Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.02. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.26.
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Eton Pharmaceuticals was 191.40% per year.
During the past 7 years, Eton Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 37.60% per year. The lowest was 37.60% per year. And the median was 37.60% per year.
The historical data trend for Eton Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eton Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | 34.81 | 18.56 |
Eton Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | 34.81 | - | 19.72 | 11.68 | 18.56 |
For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Eton Pharmaceuticals's Price-to-Free-Cash-Flow falls into.
Eton Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 3.55 | / | 0.261 | |
= | 13.60 |
Eton Pharmaceuticals's Share Price of today is $3.55.
Eton Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Eton Pharmaceuticals (NAS:ETON) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Eton Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
David Krempa | officer: Chief Business Officer | 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Sean Brynjelsen | director, officer: President & CEO | C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010 |
James R. Gruber | officer: Chief Financial Officer | 618 AMES STREET, LIBERTYVILLE IL 60048 |
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
William Wilson Troutman | officer: CFO, Treasurer & Secretary | 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010 |
Imprimis Pharmaceuticals, Inc. | 10 percent owner | 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215 |
Jennifer Mckie Adams | director | 5410 TENNESSEE AVE, NASHVILLE TN 37209 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
Norbert G Riedel | director | BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
Mark L Baum | director | C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130 |
Paul V Maier | director | 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121 |
From GuruFocus
By Value_Insider Value_Insider • 11-02-2022
By Marketwired • 08-23-2023
By GuruFocusNews GuruFocusNews • 04-11-2022
By GuruFocusNews GuruFocusNews • 04-11-2022
By Marketwired • 10-04-2023
By sperokesalga sperokesalga • 05-03-2023
By GuruFocusNews GuruFocusNews • 03-08-2022
By Marketwired • 07-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.